Tong, Gary <br/><br/>
Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers.  [electronic resource] 

 -  Clinical therapeutics  Mar 2012 
 - 654-67 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2012.01.022  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Adolescent<br/>Adult<br/>Amyloid Precursor Protein Secretases--antagonists & inhibitors<br/>Amyloid beta-Peptides--blood<br/>Basic Helix-Loop-Helix Transcription Factors--blood<br/>Biomarkers--analysis<br/>Dose-Response Relationship, Drug<br/>Dual Specificity Phosphatase 6--blood<br/>Homeodomain Proteins--blood<br/>Humans<br/>Male<br/>Oxadiazoles--administration & dosage<br/>Peptide Fragments--blood<br/>Peptides--blood<br/>Sulfonamides--administration & dosage<br/>Transcription Factor HES-1<br/>Trefoil Factor-3<br/>Young Adult